Abstract
Drugs that indirectly lower blood cholesterol through their actions in the gut have been used for many years. Their utility has been limited by poor tolerability, and hence, poor compliance. New resins are better tolerated and offer an advantage to older drugs. New strategies focusing on reducing serum cholesterol by acting on the gastrointestinal tract may hold even greater promise, combining the safety of nonsystemic agents with the acceptance of statins.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Buchwald H, Varco RL, Boen JR, et al.: Effective lipid modification by partial ilial bypass reduced long-term coronary heart disease mortality and morbidity: five year post-trial follow-up report from the POSCH. Arch Intern Med 1998, 158:1253–1261.
Grundy SM, Ahrens EH, Salen G: Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971, 78:94–121.
Davidson M, Dillon MA, Gordon B, et al.: Colesevalam hydrochloride (Cholestagel) a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999, 159:1893–1900.
Knapp HH, Schrott H, Ma P, et al.: Efficacy and safety of combination simvastatin and colesevalem in patients with primary hypercholesterolemia. Am J Med 2001, 110:352–360.
Hunninghake DB, Insull W, Toth P, et al.: Coadministration of colesevalem hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001, 158:407–416.
Donovan JD, Stypinski D, Stiles MR, et al.: Drug interactions of colesevalem hydrochloride, a novel, potent bile acid binding polymer. Cardiovasc Drug Ther 2000, 14:681–690.
Yang PC, Campion JG, Tam CY, et al.: The effect of SC-635, a potent inhibitor of the apical ileal sodium co-dependent BA transporter on cholesterol metabolism in rats. Proceedings of the XVI Bile Acid Conference. 2000. Den Haag, Netherlands,
Stein EA, Rhyne JM, McKenney J, et al.: Intestinal bile acid transporter (IBAT) inhibition: results of a 4 week pilot study of 264W94, a novel IBAT inhibitor. In Hypercholesterolemic Patients. Proceedings of Drugs Affecting Lipid Metabolism. New York, September 12, 2001.
Catapano AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Eur Heart J Suppl 2001, Suppl E:E6-E10.
Knopp RH, Gittter H, Truitt T, et al.: Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis 2001, 2(suppl):38.
Stein E: Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor Eur Heart J Suppl 2001, Suppl E:E11-E16.
Kosoglou T, Fruchart JC, Guillaume M, et al.: Coadministration of ezetimibe and fenofibrate leads to favorable effects on ApoCIII and LDL subfractions [abstract]In. European Atehrosclerosis Society. Glasgow, Scotland. May 22, 2001.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Black, D.M. Gut-acting drugs for lowering cholesterol. Curr Atheroscler Rep 4, 71–75 (2002). https://doi.org/10.1007/s11883-002-0065-8
Issue Date:
DOI: https://doi.org/10.1007/s11883-002-0065-8